4-Apr-2024
Tour de Cure Grant for Brain Cancer Research
27-Feb-2024
Appendix 4D and Half Year 2024 Financial Report
13-Feb-2024
Noxopharm extends Hudson Institute strategic partnership
22-Jan-2024
December 2023 Quarterly Activities Report and Appendix 4C
18-Dec-2023
Change of Director's Interest Notice - GM
18-Dec-2023
Notification of cessation of securities - NOX
16-Nov-2023
Results of Meeting
16-Nov-2023
Noxopharm Enhances Cash Position via R&D Rebate
16-Nov-2023
Noxopharm 2023 AGM Corporate Presentation
16-Nov-2023
Noxopharm 2023 AGM Chair Address
27-Oct-2023
Unlisted Options Expiring on 16 December 2023
18-Oct-2023
mRNA Vaccine Enhancer Shows Inflammation Reduction
13-Oct-2023
September 2023 Activities Report and Appendix 4C
9-Oct-2023
Response to ASX Query
4-Oct-2023
US FDA grants Orphan Drug Designation for CRO-67
3-Oct-2023
Trading Halt
3-Oct-2023
Pause in Trading
28-Sep-2023
Latest CRO-67 data shows success in reducing cancer growth
28-Sep-2023
2023 AGM Notice of Meeting and Proxy
28-Sep-2023
2023 AGM Letter to Shareholders and Proxy
27-Sep-2023
Annual Report to shareholders
21-Sep-2023
Change of Director's Interest Notice - FB
18-Sep-2023
Change of Director's Interest Notice - FB
31-Aug-2023
Appendix 4E and Audited Financial Statements
31-Aug-2023
Appendix 4G and Corporate Governance Statement
24-Jul-2023
Notification of cessation of securities - NOX
14-Jul-2023
June 2023 Activities Report and Appendix 4C
5-Jul-2023
Upcoming Expiry of Listed Options (ASX Code NOXOA)
5-Jul-2023
Unlisted Options expiring on 23 July 2023
5-Jul-2023
Notification of cessation of securities - NOX
3-Jul-2023
Change of Director's Interest Notice - FB
29-Jun-2023
Change of Director's Interest Notice - FB
19-Jun-2023
Change of Director's Interest Notice - FB
19-Jun-2023
Change of Director's Interest Notice - BP
19-Jun-2023
Change of Director's Interest Notice - PM
19-Jun-2023
Details of Company Address
26-May-2023
IONIC Trial Abstract Published at ASCO
19-May-2023
Study results show new Sofra drug reduces inflammation
18-May-2023
Innovative Sofra research presented at European event
10-May-2023
Change of Director's Interest Notice - FB
8-May-2023
Upcoming Expiry of Listed Options (ASX Code NOXO)
4-May-2023
Change of Director's Interest Notice - FB
24-Apr-2023
March 2023 Quarterly Activities Report and Appendix 4C
6-Apr-2023
Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
28-Mar-2023
Noxopharm Announces Novel mRNA Vaccine Enhancer
24-Feb-2023
Appendix 4D and Half Year 2023 Financial Report
22-Feb-2023
Noxopharm to Present Sofra Study at LUPUS 2023 Conference
27-Jan-2023
December 2022 Quarterly Activities Report and Appendix 4C
17-Jan-2023
DARRT-2 Trial Efficacy Phase to Commence
16-Dec-2022
NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
15-Dec-2022
Change of Director's Interest Notice - FB
15-Dec-2022
Notification of cessation of securities - NOX
6-Dec-2022
Federal Innovation Connections Grant Awarded
2-Dec-2022
IONIC Trial Progresses as Veyonda Passes Safety Milestone
21-Nov-2022
Notification of cessation of securities - NOX
17-Nov-2022
Constitution
17-Nov-2022
Results of Meeting
17-Nov-2022
Noxopharm 2022 AGM Corporate Presentation
17-Nov-2022
Noxopharm AGM 2022 Chair's Address
16-Nov-2022
CEP-2 Safety Milestone Shows Veyonda Progress
10-Nov-2022
Noxopharm Enhances Cash Position via R&D Rebate
25-Oct-2022
Change in substantial holding
21-Oct-2022
September 2022 Quarterly Activities Report and Appendix 4C
18-Oct-2022
2022 AGM Notice of Meeting and Proxy
18-Oct-2022
2022 AGM Letter to Shareholders and Proxy
7-Oct-2022
Unlisted Options Expiring on 21 November 2022
26-Sep-2022
Noxopharm 2022 Annual Report
20-Sep-2022
Final Director's Interest Notice - GK
19-Sep-2022
Resignation of Dr Graham Kelly as Non-Executive Director
14-Sep-2022
Novel Dual-cell Therapy Results in Pancreatic Cancer
2-Sep-2022
Response to ASX Price Query (Correction to ASX Ticker)
2-Sep-2022
Response to ASX Price Query
25-Aug-2022
Appendix 4E and Audited Financial Statements
25-Aug-2022
Appendix 4G and Corporate Governance Statement
16-Aug-2022
Noxopharm & UNSW Pancreatic Cancer Research at US Conference
9-Aug-2022
CEP-2 Trial Passes Safety Milestone
2-Aug-2022
DARRT-2 Trial Safety Milestone and European Site Activated
27-Jul-2022
June 2022 Quarterly Activities Report and Appendix 4C
5-Jul-2022
Mayo Clinic and Washington Uni Join Noxopharm Sarcoma Trial
22-Jun-2022
$1.45M Grant to Hudson Institute for Noxopharm Collaboration
14-Jun-2022
Hudson Institute Collaboration Secures mRNA Victoria Acceleration Fund Grant
7-Jun-2022
Noxopharm Corporate Presentation
27-May-2022
Veyonda Abstract Published at ASCO Annual Meeting 2022
28-Apr-2022
March 2022 Quarterly Activities Report and Appendix 4C
22-Mar-2022
Orphan Drug Designation Granted to Noxopharm by US FDA
28-Feb-2022
First Patient Treated in CEP-2 Sarcoma Trial
21-Feb-2022
Appendix 4D and Half Year 2022 Financial Report
1-Feb-2022
Initial Director's Interest Notice - GM
27-Jan-2022
December 2021 Quarterly Activities Report and Appendix 4C
10-Jan-2022
Noxopharm Presents at H.C. Wainwright BioConnect Conference
7-Jan-2022
Noxopharm Receives A$5.865M R & D Tax Rebate
5-Jan-2022
Noxopharm Announces Leadership Transition
14-Dec-2021
Noxopharm DARRT-2 Cancer Trial Update
2-Dec-2021
Notification of cessation of securities - NOX
2-Dec-2021
Change of Director's Interest Notice - GK
17-Nov-2021
Noxopharm Annual General Meeting Results
17-Nov-2021
Licencing Deal Expands Noxopharm Drug Opportunities
17-Nov-2021
Noxopharm 2021 AGM Corporate Presentation
17-Nov-2021
Noxopharm 2021 AGM Chairmans Address
16-Nov-2021
Retraction of Grant Announcement
15-Nov-2021
Trading Halt
15-Nov-2021
Noxopharm Awarded A$8.8M Aust Govt Grant for Sarcoma Trial
4-Nov-2021
DARRT-2 Trial Commences in the U.S.
29-Oct-2021
Unlisted Options Expiring on 30 November 2021
26-Oct-2021
Veyonda and Opdivo IONIC Study First Patient Dosed
25-Oct-2021
Patent Granted for Veyonda and Low Dose Chemotherapy
20-Oct-2021
Jobkeeper s323DB Notice
15-Oct-2021
2021 AGM Notice of Meeting and Proxy
15-Oct-2021
2021 AGM Letter to Shareholders and Proxy
14-Oct-2021
September 2021 Quarterly Activities Report and Appendix 4C
29-Sep-2021
Cleansing Notice
29-Sep-2021
Application for quotation of securities - NOX
27-Sep-2021
Veyonda Achieves Important U.S. Patent Claims
10-Sep-2021
Noxopharm 2021 Annual Report
9-Sep-2021
Noxopharm Updated Corporate Presentation
30-Aug-2021
Change of Registered Office and Principal Place of Business
26-Aug-2021
Appendix 4E and Audited Financial Statements
26-Aug-2021
Appendix 4G and Corporate Governance Statement
23-Aug-2021
Cleansing Notice
23-Aug-2021
Application for quotation of securities - NOX
23-Aug-2021
Pre-clinical Data Supports a Role for Veyonda in COVID-19
23-Aug-2021
NOXCOVID Program to Expand After Positive Phase 1 Results
19-Aug-2021
Trading Halt
13-Aug-2021
Cleansing Notice
13-Aug-2021
Application for quotation of securities - NOX
11-Aug-2021
Additional Information on US NCI Collaboration
9-Aug-2021
NOX and US Govt Peak Cancer Agency Announce Collaboration
5-Aug-2021
Veyonda Survival Advantage in LuPSMA Therapy Confirmed
27-Jul-2021
June 2021 Quarterly Activities Report and Appendix 4C
1-Jul-2021
DARRT-2 Study Receives IND Approval from FDA
29-Jun-2021
Noxopharm Secures Key European Patent Allowance for Veyonda
28-Jun-2021
Noxopharm Corporate Presentation
21-Jun-2021
Cleansing Notice
21-Jun-2021
Application for quotation of securities - NOX
10-Jun-2021
DARRT-2 Study Update and Clarification
8-Jun-2021
The Noxopharm Newsletter June 2021
4-Jun-2021
Noxopharm Set to Benefit From Novartis ASCO Data
31-May-2021
Becoming a substantial holder
31-May-2021
Change of Director's Interest Notice - FB
31-May-2021
Change of Director's Interest Notice - BP
31-May-2021
Cleansing Notice
31-May-2021
Appendix 2A
31-May-2021
Appendix 3G
31-May-2021
Noxopharm Extraordinary General Meeting Results
31-May-2021
New Independent Trial Data Supports Potential of Veyonda
13-May-2021
Noxopharm to Present to Share Cafe Hidden Gems Webinar
12-May-2021
NOXCOVID Trial Achieves Full Enrolment
7-May-2021
Cleansing Notice
7-May-2021
Appendix 2A
7-May-2021
Veyonda FDA Approved Trial to Commence
4-May-2021
Securities Trading Policy
30-Apr-2021
Cleansing Notice
30-Apr-2021
Appendix 2A
30-Apr-2021
Change of Director's Interest Notice - BP
30-Apr-2021
Lapsing of Unlisted Options
30-Apr-2021
Publications Positive Review of Veyonda in Chemotherapy
29-Apr-2021
Notice of General Meeting/Proxy Form
27-Apr-2021
March Quarterly Activities Report and Appendix 4C
22-Apr-2021
Veyonda Showing Potential to Prevent Cytokine Storm
22-Apr-2021
Pause in Trading
12-Apr-2021
Cleansing Notice
12-Apr-2021
Appendix 2A
6-Apr-2021
Veyonda Patent Lodged for Major Septic Shock Opportunity
29-Mar-2021
Corporate Presentation for Switzer Virtual Investor Day
19-Mar-2021
Noxopharm IONIC Immuno-Oncology Trial Commences
16-Mar-2021
ASX Small-Mid Cap Conference Corporate Presentation
8-Mar-2021
NOXCOVID Trial Advances to Final Stage
5-Mar-2021
Noxopharm Presents to H.C. Wainwright Global Conference
4-Mar-2021
Cleansing Notice
4-Mar-2021
Appendix 2A
2-Mar-2021
Noxopharm Receives A$4.59M Federal Gov R&D Tax Rebate
1-Mar-2021
Proposed issue of Securities - NOX
1-Mar-2021
Lapsing of Unlisted Options and Shortfall Shares
1-Mar-2021
Change of Director's Interest Notice - PM
26-Feb-2021
Change in substantial holding
26-Feb-2021
Change of Director's Interest Notice - GK
26-Feb-2021
Cleansing Notice
26-Feb-2021
Appendix 2A
24-Feb-2021
Company Announcement Regarding Appendix 3Y Disclosures
24-Feb-2021
Change in substantial holding
24-Feb-2021
Change of Director's Interest Notice - GK
23-Feb-2021
Noxopharm Updated Corporate Presentation February-March 2021
19-Feb-2021
Option Underwriting Agreement to Secure Funds
19-Feb-2021
Cleansing Notice
19-Feb-2021
Appendix 2A
16-Feb-2021
Noxopharm CEO Letter to Shareholders February 2021
16-Feb-2021
Appendix 4D and Half Year Financial Report
15-Feb-2021
Cleansing Notice
15-Feb-2021
Appendix 2A
15-Feb-2021
LuPIN Survival Outcome Confirmed by Conference Presentation
9-Feb-2021
Major Survival Benefit in Prostate Cancer Patients Announced
5-Feb-2021
Cleansing Notice
5-Feb-2021
Appendix 2A
3-Feb-2021
Cleansing Notice
3-Feb-2021
Appendix 2A
28-Jan-2021
Noxopharm To Present to ShareCafe Hidden Gems Webinar
25-Jan-2021
Noxopharm Dec 2020 Quarterly Activities Report & Appendix 4C
22-Jan-2021
Cleansing Notice
22-Jan-2021
Appendix 2A
13-Jan-2021
NOXCOVID Study Advances
12-Jan-2021
Unlisted Options Expiring 28 February 2021
6-Jan-2021
Noxopharm Shareholder Update 2021
23-Dec-2020
Federal Government Approved Future Overseas R&D Expenditure
15-Dec-2020
Cleansing Notice
15-Dec-2020
Appendix 2A
15-Dec-2020
Change of Director's Interest Notice - BP
15-Dec-2020
Change of Director's Interest Notice - FB
15-Dec-2020
Appendix 3G
11-Dec-2020
December Investor Webinar Recording
10-Dec-2020
Change in substantial holding
10-Dec-2020
Cleansing Notice
10-Dec-2020
Appendix 2A
8-Dec-2020
Noxopharm Corporate Presentation December Investor Webinar
7-Dec-2020
Pre-Clinical Breakthrough Discovery Set to Expand Pipeline
4-Dec-2020
Noxopharm December Investor Webinar Details
3-Dec-2020
Cleansing Statement
3-Dec-2020
Proposed issue of Securities - NOX
3-Dec-2020
Noxopharm Completes A$23m Placement to Fund Clinical Studies
1-Dec-2020
Appendix 2A
1-Dec-2020
Trading Halt
27-Nov-2020
Change of Director's Interest Notice - PM
27-Nov-2020
Lapsing of Unlisted Options
18-Nov-2020
Change of Director's Interest Notice - GK
18-Nov-2020
Cleansing Notice
18-Nov-2020
Appendix 2A
18-Nov-2020
Appendix 3G
18-Nov-2020
Further Independent Support for Veyonda as a Major I-O Drug
17-Nov-2020
Noxopharm Annual General Meeting Results
17-Nov-2020
Noxopharm 2020 AGM Corporate Update
17-Nov-2020
2020 AGM Chairman's Address
13-Nov-2020
Independent Discovery Validates DARRT Cancer Therapy
9-Nov-2020
Veyonda To Be Tested In Combination With Opdivo In Trial
5-Nov-2020
Dedicated Septic Shock Company Established
5-Nov-2020
NOXCOVID Study Cleared To Expand
3-Nov-2020
2020 Annual General Meeting Reminder
26-Oct-2020
Cleansing Notice
26-Oct-2020
Appendix 2A
26-Oct-2020
First Two Cohorts Enrolled in NOXCOVID Study
15-Oct-2020
Noxopharm September 2020 Quarterly Activities Report & Appendix 4C
14-Oct-2020
Cover Letter and Proxy Form - Annual General Meeting
14-Oct-2020
Notice of Annual General Meeting and Proxy Form
12-Oct-2020
LuPIN Study Achieves Final Patient Treatment
9-Oct-2020
Noxopharm CMO Discusses the NOXCOVID trial
9-Oct-2020
Unlisted Options Expiring 27 November 2020
9-Oct-2020
Cleansing Notice
9-Oct-2020
Appendix 2A
6-Oct-2020
Noxopharm Loan Terms Amended to Benefit Company
2-Oct-2020
First COVID-19 Patient Treated in Veyonda Study
21-Sep-2020
Noxopharm Corporate Presentation September 2020
18-Sep-2020
Noxopharm Appoints US Corporate Advisory and Consulting Firm
17-Sep-2020
Notification of Date of 2020 Annual General Meeting
15-Sep-2020
Annual Report to shareholders
15-Sep-2020
Appendix 4G and Corporate Governance Statement
9-Sep-2020
Noxopharm Appoints New Chair
8-Sep-2020
Global CRO To Execute DARRT-2 Prostate Cancer Study
1-Sep-2020
Veyonda COVID-19 Study Approved For Immediate Start
31-Aug-2020
Final Director's Interest Notice - ID
31-Aug-2020
Appendix 4E and Audited Financial Statements FY2020
31-Aug-2020
Appendix 4G and Corporate Governance Statement
31-Aug-2020
Noxopharm Announces Board Changes
14-Aug-2020
Appendix 2A - Shares
14-Aug-2020
Cleansing Notice
14-Aug-2020
Appendix 2A - Underwriter Options
14-Aug-2020
Results of Meeting
14-Aug-2020
Noxopharm August 2020 EGM Corporate Presentation
11-Aug-2020
Peer-Reviewed Publication Strengthens Case For Veyonda
6-Aug-2020
Noxopharm Extraordinary General Meeting Reminder
29-Jul-2020
Noxopharm June 2020 Quarterly Activities Report & Appendix 4C
24-Jul-2020
Change of Director's Interest Notice - FB
24-Jul-2020
Notice of Contravention of Listing Rule 10.11
23-Jul-2020
Noxopharm Discusses Converting Cold to Hot Cancer Tumours
22-Jul-2020
Receipt of cash payment for collateral shares
20-Jul-2020
Data Shows Idronoxil Holds Key to Problem of COLD Cancers
14-Jul-2020
Noxopharm July 2020 Newsletter Released
14-Jul-2020
Letter to Shareholders - Extraordinary General Meeting
14-Jul-2020
Notice of Extraordinary General Meeting/Proxy Form
8-Jul-2020
Corporate Presentation for the Reach Markets Virtual Event
3-Jul-2020
Ceasing to be a substantial holder
29-Jun-2020
Change of Director's Interest Notice - FB
22-Jun-2020
Change in substantial holding - amended
22-Jun-2020
Change in substantial holding
22-Jun-2020
Noxopharm Chair Letter to Shareholders
19-Jun-2020
COVID-19 Trial Program to Commence in Europe
18-Jun-2020
Change in substantial holding
18-Jun-2020
Change in substantial holding
18-Jun-2020
Change of Director's Interest Notice - BP
18-Jun-2020
Change of Director's Interest Notice - FB
18-Jun-2020
Change of Director's Interest Notice - PM
18-Jun-2020
Change of Director's Interest Notice - GK
18-Jun-2020
Appendix 2A - shares
18-Jun-2020
Appendix 2A - options
15-Jun-2020
Pro-rata Non-Renounceable Rights Issue Fully Allocated
9-Jun-2020
Rights Issue Close Date
5-Jun-2020
Webcast Overview of ASCO 2020 Annual Meeting NOX Posters
4-Jun-2020
Change of Director's Interest Notice - PM
4-Jun-2020
Change of Director's Interest Notice - ID
1-Jun-2020
Appendix 3G Adjustment to Option Exercise Prices
1-Jun-2020
ASCO 2020 Highlights NOX66 Potential in Late-Stage Cancer
28-May-2020
Listing Rule 6.22.2 Adjustment to Option Exercise Prices
22-May-2020
Proposed issue of Securities - NOX
21-May-2020
Despatch of Pro Rata Entitlement Offer Documents
19-May-2020
FDA allows Veyonda Pre-IND Submission for COVID-19
14-May-2020
Noxopharm ASCO Abstracts Live
13-May-2020
Appendix 2A
13-May-2020
Entitlement Offer Prospectus
13-May-2020
Entitlement Offer - Letter to Optionholders
13-May-2020
Entitlement Offer - Letter to Ineligible Shareholders
13-May-2020
Entitlement Offer - Letter to Eligible Shareholders
13-May-2020
Proposed issue of Securities - NOX
13-May-2020
$7.9 Million Fully Underwritten Entitlement Offer Announced
8-May-2020
Initial Director's Interest Notice - FB
8-May-2020
Appointment of New Board Member
7-May-2020
Trading Halt
1-May-2020
Change in substantial holding
1-May-2020
Change in substantial holding
30-Apr-2020
Noxopharm March 2020 Quarterly Report & Appendix 4C
30-Apr-2020
Abscopal Responses Achieved in Prostate Cancer
23-Apr-2020
Pipeline Expands With Potential New Brain Cancer Treatment
21-Apr-2020
Approval to be sought for COVID-19 Clinical Study in U.S.
20-Apr-2020
Receipt of cash payment for collateral shares
7-Apr-2020
Noxopharm trial data to be presented at ASCO 2020
2-Apr-2020
Updated Noxopharm Virtual Roadshow Corporate Presentation
1-Apr-2020
Noxopharm Investigating Potential COVID-19 Treatment
31-Mar-2020
Noxopharm Virtual Roadshow Corporate Presentation
26-Mar-2020
Initial Director's Interest Notice
26-Mar-2020
Appointment of New Board Member
17-Mar-2020
Veyonda Awarded First Allowed Patent Application
13-Mar-2020
Veyonda Clinical Program Update and Guidance
3-Mar-2020
LuPIN Prostate Cancer Trial Fully Recruited
27-Feb-2020
Noxopharm Corporate Presentation February 2020
25-Feb-2020
Half Year Accounts and Chairman Letter
21-Feb-2020
Section 708 Certificate
21-Feb-2020
Appendix 2A
21-Feb-2020
FDA grants IND approval to Veyonda
18-Feb-2020
Termination of Convertible Loan
18-Feb-2020
Section 708 Certificate
18-Feb-2020
Appendix 2A
18-Feb-2020
Noxopharm Alliance With GenesisCare
14-Feb-2020
Proposed issue of Securities - NOX
14-Feb-2020
$8.1M Financing & Re-Set of Capital Structure
14-Feb-2020
Pronounced survival benefit in LuPIN interim trial data
12-Feb-2020
Trading Halt
11-Feb-2020
LuPIN interim trial data to be presented at ASCO GU 2020
6-Feb-2020
Lapsing of Unlisted Options
31-Jan-2020
Noxopharm December 2019 Quarterly Activities Report & Appendix 4C
29-Jan-2020
Noxopharm Non-Deal Roadshow Presentation
20-Jan-2020
Appendix 3B
16-Jan-2020
Listing of Nyrada Inc. spin-off on ASX
16-Jan-2020
Becoming a substantial holder for NYR
15-Jan-2020
Noxopharm Corporate Presentation
27-Dec-2019
Ceasing to be a substantial holder
23-Dec-2019
Change of Director's Interest Notice - GK
23-Dec-2019
Section 708 Certificate
23-Dec-2019
Appendix 3B
20-Dec-2019
DARRT-1 Clinical Data Webinar
17-Dec-2019
Nyrada IPO Offer Fully Subscribed
13-Dec-2019
Unlisted Options Expiring 18 January 2020
9-Dec-2019
Lodgement of Nyrada Inc Supplementary Prospectus
4-Dec-2019
Nyrada Inc Initial Public Offering Opens
3-Dec-2019
Section 708 Certificate - Notes
3-Dec-2019
Section 708 Certificate
3-Dec-2019
Appendix 3B
3-Dec-2019
AU$2.4m Increase to Funding Agreement
3-Dec-2019
Section 708 Certificate
3-Dec-2019
Appendix 3B
2-Dec-2019
Positive DARRT-1 Data in Late-Stage Prostate Cancer
28-Nov-2019
Trading Halt
26-Nov-2019
Lodgement of Nyrada Inc Prospectus - Initial Public Offering
26-Nov-2019
Lodgement of Nyrada Inc Prospectus - Initial Public Offering - Interactive
20-Nov-2019
Constitution
20-Nov-2019
Results of Meeting
20-Nov-2019
Noxopharm 2019 AGM Corporate Presentations
12-Nov-2019
DARRT-1 Interim Data Presented To Conference
12-Nov-2019
LuPIN Data Being Presented To Conference
6-Nov-2019
Appointment of Chief Commercial Officer
30-Oct-2019
Noxopharm October 2019 Newsletter
30-Oct-2019
Appendix 4C - Quarterly Report for The Quarter Ending September 30, 2019
28-Oct-2019
Dr Graham Kelly to Assume CEO Role
25-Oct-2019
Appendix 3B
25-Oct-2019
Section 708 Certificate
22-Oct-2019
NOX and Nyrada TechKnow Invest Roadshow Presentations
21-Oct-2019
Durable Anti-Cancer Effect Confirmed in DARRT-1 Study
18-Oct-2019
Notice of 2019 Annual General Meeting & Proxy Form
18-Oct-2019
Potential Fundamental Change in Treatment of Brain Cancer
16-Oct-2019
New Executive Appointments and Board Change
16-Oct-2019
Final Director's Interest Notice
2-Oct-2019
Noxopharm 2019 Annual General Meeting Details
2-Oct-2019
FNN Interview: The LuPIN trial with Veyonda in prostate cancer
30-Sep-2019
Further Review Shows Major Clinical Benefits from Veyonda
26-Sep-2019
Corporate Governance Statement - Appendix 4G
26-Sep-2019
Corporate Governance Statement
26-Sep-2019
Section 708 Certificate
26-Sep-2019
Appendix 3B
26-Sep-2019
Annual Report to Shareholders
24-Sep-2019
Departure of Dr Van Wyk
17-Sep-2019
Veyonda and Radiotherapy Profiled at Key Oncology Meeting
16-Sep-2019
Results of Meeting
16-Sep-2019
NOX EGM Chairman's Address and Presentation
12-Sep-2019
CHANGE OF DIRECTOR'S INTEREST NOTICE - GK
10-Sep-2019
CHANGE OF DIRECTOR'S INTEREST NOTICE - GK
29-Aug-2019
Appendix 4E and Audited Financial Statements FY19
28-Aug-2019
Addendum to Notice of Extraordinary General Meeting
28-Aug-2019
More Evidence that Veyonda Enhances RT in Prostate Cancer
23-Aug-2019
NOX Receives FY19 Federal Government R&D Tax Rebate
23-Aug-2019
Appendix 3B
23-Aug-2019
Cleansing Statement
21-Aug-2019
Pre-Clinical Evidence Confirms Veyonda Abscopal Effect
15-Aug-2019
Lead Manager Appointed for Proposed Nyrada IPO
12-Aug-2019
Notice of Extraordinary General Meeting/Proxy Form
9-Aug-2019
Noxopharm Corporate Update Interview
7-Aug-2019
Noxopharm August 2019 Corporate Presentation
2-Aug-2019
NOX Releases Initial Newsletter for Nyrada Subsidiary
29-Jul-2019
Appendix 4C - Quarterly Report for the quarter ending June 30, 2019
25-Jul-2019
Appendix 3B
25-Jul-2019
Section 708 Certificate
23-Jul-2019
Appendix 3B
23-Jul-2019
Section 708 Certificate
19-Jul-2019
Initial Director's Interest Notice
19-Jul-2019
Final Director's Interest Notice
19-Jul-2019
NOX Announces AU$26 Million Funding Facility
17-Jul-2019
NOX Releases Latest Newsletter
16-Jul-2019
Board Changes Ahead of Corporate Growth
2-Jul-2019
LuPIN-1 Interim Results Presentation Recording at SNMMI Annual Meeting 2019
26-Jun-2019
Conference Hears of Positive Interim Data from LuPIN Trial
7-Jun-2019
NOX Subsidiary, Nyrada Inc, Receives R&D Rebate
6-Jun-2019
Noxopharm Corporate Presentation June 2019
30-May-2019
DARRT-1 Study Fully Enrolled
23-May-2019
Promising Data Leads to Expansion of LuPIN Trial
20-May-2019
LuPIN Trial Demonstrates High Rates of Response
8-May-2019
Change of Director's Interest Notice - GK
8-May-2019
Appendix 3B
2-May-2019
DARRT Treatment Has Lasting Disease Control at Six Months
29-Apr-2019
Veyonda and Immuno-Oncology Effect Explained
26-Apr-2019
Appendix 4C - Quarterly
23-Apr-2019
Change in Noxopharm Limited Board Structure
16-Apr-2019
Idronoxil Confirmed as New Immuno-Oncology Drug
10-Apr-2019
Veyonda Chemotherapy Enhancement Program to be Expanded
8-Apr-2019
Securities to be released from Voluntary Escrow
5-Apr-2019
Updated Top 20 shareholder List
25-Mar-2019
Appendix 3B
25-Mar-2019
Section 708 Certificate
21-Mar-2019
Becoming a substantial holder
19-Mar-2019
KZA: Kazia sells stake in Noxopharm
6-Mar-2019
NOX provides update to Nyrada Note Holders
5-Mar-2019
New Corporate Presentation Released
21-Feb-2019
Noxopharm to expedite Veyonda Clinical Program
21-Feb-2019
Appendix 4D and Half Year Accounts
14-Feb-2019
Change of Director's Interest Notice - GK
6-Feb-2019
FNN interview with Nox Chief Medical Officer on Interim Data
6-Feb-2019
Veyonda and Radiotherapy Delivers Clinical Benefits
1-Feb-2019
Appendix 3B
29-Jan-2019
Appendix 4C - quarterly report for the quarter ended December 31, 2018
14-Jan-2019
Principal Investigator Discusses LuPIN-1 Study
21-Dec-2018
Change of Director's Interest Notice - GK
21-Dec-2018
Section 708 Certificate
21-Dec-2018
Appendix 3B
20-Dec-2018
NOX Receives $3.26M Federal Govt R&D Rebate
11-Dec-2018
DARRT-1 study advancing on basis of positive clinical data
29-Nov-2018
NOX announces Positive Data from CEP-1 Study of Veyonda
21-Nov-2018
Initial Director's Interest Notice
21-Nov-2018
Results of Meeting
21-Nov-2018
Appointment of Mr John Moore as Non-Executive Director
21-Nov-2018
NOX 2018 AGM Presentations
20-Nov-2018
NOX 2018 AGM Information
13-Nov-2018
NOX to Present Clinical Data at COSA Annual Meeting
8-Nov-2018
Corporate Presentation
26-Oct-2018
Appendix 4C - Quarterly report for the quarter ended September 30, 2018
22-Oct-2018
NOX makes key executive appointment
5-Oct-2018
Notice of Annual General Meeting & Proxy Form
4-Oct-2018
Noxopharm Releases Report on Key Progress of Subsidiary
2-Oct-2018
Section 708 Certificate
2-Oct-2018
Appendix 3B
28-Sep-2018
Change of Director's Interest Notice - PM
28-Sep-2018
Section 708 Certificate
28-Sep-2018
Appendix 3B
28-Sep-2018
Change of Registry Address: Automic P/L - Sydney Office
27-Sep-2018
Annual Report to shareholders
27-Sep-2018
Corporate Governance Statement - Appendix 4G
27-Sep-2018
Corporate Governance Statement - 2018
24-Sep-2018
NOX Subsidiary Announces Important Drug Discovery
5-Sep-2018
NOX to support expanded LuPIN study
30-Aug-2018
Appendix 4E and Audited Financial Statements
27-Aug-2018
Nyrada-Key progress with cholesterol-lowering drug candidate
20-Aug-2018
VEYONDA - Registered Trade Mark for NOX66
9-Aug-2018
Change of Director's Interest Notice - GK
9-Aug-2018
Change of Director's Interest Notice - PM
9-Aug-2018
Change of Director's Interest Notice - ID
9-Aug-2018
Appendix 3B
8-Aug-2018
Interim NOX66 Radiotherapy Clinical Data
30-Jul-2018
Appendix 4C- Quarterly report for the quarter ended June 30, 2018
10-Jul-2018
Securities to be released from Escrow
9-Jul-2018
Release of DARRT-1 Preliminary Safety Data
5-Jul-2018
Pre-Clinical data confirms Radio-Enhancing potential
7-Jun-2018
Noxopharm Corporate Presentation for Public Briefing
5-Jun-2018
End-of-Study Clinical Data shows benefit of NOX66
31-May-2018
Noxopharm 2018 Mid-Year Investor Briefings
28-May-2018
Section 708 Certificate
28-May-2018
Appendix 3B
22-May-2018
NOX to present at American Society of Clinical Oncology
21-May-2018
Change in substantial holding
21-May-2018
Securities to be released from Voluntary Escrow
21-May-2018
Section 708 Certificate
21-May-2018
Appendix 3B
18-May-2018
Noxopharm 2018 Mid-Year Investor Briefings
15-May-2018
Results of Meeting
7-May-2018
NOX CEO interview updates the company's current R&D program
3-May-2018
NOX CEO interview on near complete NOX66 chemotherapy trial
27-Apr-2018
NOX CEO interview on Radiotherapy Clinical Programs
27-Apr-2018
Appendix 4C - quarterly
17-Apr-2018
St Vincent's Hospital study passes first milestone
9-Apr-2018
Notice of Extraordinary General Meeting / Proxy Form
6-Apr-2018
Change in substantial holding
6-Apr-2018
Change in substantial holding
5-Apr-2018
DARRT-1 Clinical Study commences
5-Apr-2018
NOX Mid-Year Briefings
29-Mar-2018
Section 708 Certificate
29-Mar-2018
Appendix 3B
23-Mar-2018
NOX raises $10.8 M to advance clinical program
21-Mar-2018
Trading Halt
21-Mar-2018
Evidence of Abscopal Responses in Patients
12-Mar-2018
Corporate Presentation - Post Interim Clinical Data Release
9-Mar-2018
FNN Interview with Noxopharm CEO
6-Mar-2018
NOX Reports NOX66 Clinical Data
5-Mar-2018
Trading Halt
23-Feb-2018
Update accompanying Half Year Report
23-Feb-2018
Appendix 4D and Half Year Accounts
16-Feb-2018
NOX closes $4m capital raising for US subsidiary Nyrada Inc
31-Jan-2018
Appendix 4C - quarterly
25-Jan-2018
Section 708 Certificate
25-Jan-2018
Appendix 3B
18-Jan-2018
Section 708 Certificate
18-Jan-2018
Appendix 3B
17-Jan-2018
NOX receives FY17 R&D Tax Rebate
27-Dec-2017
Kazia Therapeutics Ltd and Noxopharm Ltd
21-Dec-2017
EOY Guidance on 2018 NOX66 Clinical Development Strategy
19-Dec-2017
Section 708 Certificate
19-Dec-2017
Appendix 3B
14-Dec-2017
Response to ASX Price Query
12-Dec-2017
Appendix 3B
11-Dec-2017
Change of Registered Office
7-Dec-2017
Section 708 Certificate
7-Dec-2017
Appendix 3B
6-Dec-2017
NOX Open Briefing Corporate Presentation
4-Dec-2017
Compassionate use of NOX66 in Patients
1-Dec-2017
Nyrada Inc Opens Capital Raise - Memorandum Released
29-Nov-2017
Change of Director's Interest Notice - PM
29-Nov-2017
Change of Director's Interest Notice - ID
29-Nov-2017
Appendix 3B
29-Nov-2017
Webcast of NOX 2017 AGM
29-Nov-2017
NYX-104 delivers Key Proof-of-Concept in Stroke Animal Model
28-Nov-2017
Invitation to Open Briefing
27-Nov-2017
Results of Meeting
27-Nov-2017
AGM Presentations
23-Nov-2017
Clarification of Incorrect Information
23-Nov-2017
Trading Halt
21-Nov-2017
NOX 2017 AGM Webcast
21-Nov-2017
Completion of Transfer of Shares to Nyrada Inc
20-Nov-2017
Promising Interim Clinical Data for NOX66
17-Nov-2017
Trading Halt
16-Nov-2017
1st Patient treated in Lupin Study at St Vincent's Hospital
15-Nov-2017
Section 708 Certificate
15-Nov-2017
Appendix 3B
13-Nov-2017
NOX making three presentations at COSA
7-Nov-2017
Section 708 Certificate
7-Nov-2017
Appendix 3B
6-Nov-2017
Results of Meeting
6-Nov-2017
EGM Presentations
3-Nov-2017
UNSW collaboration confirms drug designed for stroke victims
30-Oct-2017
Appendix 4C – Quarterly report for the quarter ended September 30, 2017
26-Oct-2017
Notice of Annual General Meeting/Proxy Form
26-Oct-2017
Annual Report to shareholders
23-Oct-2017
Update - General Meeting Agenda
19-Oct-2017
October 2017 Open Briefing Corporate Presentation
13-Oct-2017
Invitation to Open Briefing
4-Oct-2017
Establishment of Nyrada Inc. - Extraordinary General Meeting
27-Sep-2017
Australian NOX66 - Radiotherapy Study Opens
25-Sep-2017
Establishment of Nyrada Inc.
12-Sep-2017
Positive Clinical Outcomes for NOX66 at ESMO Conference
7-Sep-2017
Change in substantial holding
6-Sep-2017
Change in substantial holding
4-Sep-2017
Placement completed App 3B, s708 Notice, LR7.1A4(b) Notice
4-Sep-2017
NOX CEO Interview explains recent Brain Cancer Announcement
31-Aug-2017
Appendix 4E and Audited Financial Statements
31-Aug-2017
Corporate Governance Statement - Appendix 4G
31-Aug-2017
Corporate Governance Statement
29-Aug-2017
Important Brain Cancer Findings for NOX66 Program
24-Aug-2017
Reinstatement to Official Quotation
24-Aug-2017
Noxopharm raises $5.5 million to advance clinical program
23-Aug-2017
Suspension from Official Quotation
21-Aug-2017
Trading Halt Request
21-Aug-2017
Trading Halt
8-Aug-2017
NOX Corporate Presentation ahead of Conference
31-Jul-2017
Appendix 4C - quarterly
27-Jul-2017
NOX Research Report prepared by APP Securities
25-Jul-2017
CEO Interview with FNN - Singapore and HK Roadshow
25-Jul-2017
New Corporate Presentation
6-Jul-2017
Noxopharm provides update on NOX66 Clinical Trial Program
19-Jun-2017
Idronoxil data provides hope to treat secondary brain cancer
5-Jun-2017
NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
30-May-2017
New Corporate Presentation
29-May-2017
St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
24-May-2017
NOX makes strategic commitment to treatment of rare cancers
18-May-2017
Noxopharm Mid Year Investor Briefings
2-May-2017
Market Guidance for Next Six Months
27-Apr-2017
Appendix 4C - quarterly
10-Apr-2017
FNN Interview with NOX CEO Explaining Idronoxil-C Discovery
10-Apr-2017
NOX Files Patent Application on 'Smart' Idronoxil
3-Apr-2017
Appendix 3B
27-Mar-2017
NOX and Monash Uni Collaboration Receives Federal Grant
16-Mar-2017
Noxopharm and UNSW combine on stroke project
10-Mar-2017
Gold Coast Qld Mid-Year Briefing Details
7-Mar-2017
Notification of Release of Restricted Securities Escrow
3-Mar-2017
NOX researching rare Abscopal Response
24-Feb-2017
Appendix 4D and Half Year Accounts
24-Feb-2017
NOX Presentation and Interview ASX The CEO Sessions
21-Feb-2017
ASX CEO Presentation Feb 2017 slides
15-Feb-2017
Upcoming Events and Presentations
3-Feb-2017
Change of Principal Place of Business
1-Feb-2017
Brain Cancer Study Commences
31-Jan-2017
First NOX66 Clinical Trial to Commence
30-Jan-2017
Appendix 4C – Quarterly report for the quarter ended 31 December 2016
16-Jan-2017
Appointment of New Company Secretary
9-Jan-2017
Appendix 3B
20-Dec-2016
Change in substantial holding
20-Dec-2016
Change of Director's Interest Notice - ID
20-Dec-2016
Change of Director's Interest Notice - GK
20-Dec-2016
Market Capitalisation - further update
20-Dec-2016
Appendix 3B
19-Dec-2016
Market Capitalisation Update
23-Nov-2016
Results of Meeting
23-Nov-2016
Breakthrough in Delivering Idronoxil into Brain
22-Nov-2016
Corporate Presentation Updated
22-Nov-2016
Corporate Presentation Providing Clinical Program Guidance
17-Nov-2016
Medical Advisors Appointed for Extensive Clinical Program
14-Nov-2016
Change in substantial holding DH
31-Oct-2016
Appendix 4C - quarterly
24-Oct-2016
Noxopharm 2016 AGM Sydney Briefing
21-Oct-2016
Annual Report to shareholders
20-Oct-2016
Corporate Presentation
3-Oct-2016
Appendix 4G
30-Sep-2016
Amendment to Preliminary Final Report
12-Sep-2016
Corporate Presentation for Roadshow
31-Aug-2016
Preliminary Final Report
25-Aug-2016
Change in substantial holding
22-Aug-2016
Change in substantial holding DH
22-Aug-2016
Noxopharm to Initiate Radiotherapy Clinical Studies
19-Aug-2016
Change of Director's Interest Notice - GK
10-Aug-2016
Becoming a substantial holder
10-Aug-2016
Becoming a substantial holder
10-Aug-2016
Becoming a substantial holder
10-Aug-2016
Initial Director's Interest Notice - PM
10-Aug-2016
Initial Director's Interest Notice - ID
10-Aug-2016
Initial Director's Interest Notice - GK
9-Aug-2016
Noxopharm Limited commences trading on ASX
8-Aug-2016
Performance Share Terms
8-Aug-2016
Option Terms
8-Aug-2016
Restricted Securities and Capital Structure
8-Aug-2016
Securities Trading Policy
8-Aug-2016
Financial Accounts
8-Aug-2016
Constitution
8-Aug-2016
ASX Market Release - Admission to Official List
8-Aug-2016
Appendix 1A & Information Form and Checklist
8-Aug-2016
Top 20 Holders
8-Aug-2016
Distribution Schedule
8-Aug-2016
Company's Admission Disclosures
8-Aug-2016
ASX Market Release - Pre-Quotation Disclosure
8-Aug-2016
Prospectus
8-Aug-2016
ASX Notice - Admission and Commencement of Quotation